The Irshad Group brings together expertise in immunology, oncology, and clinical trial design to investigate how immune dysfunction contributes to cancer progression and treatment failure. We specialise in high-dimensional immune profiling, spatial single-cell analysis, and longitudinal sampling across tumour tissue, lymph nodes, and peripheral blood. Our research aims to identify biomarkers of response and resistance, understand mechanisms of immune escape, and uncover new therapeutic targets to guide immunotherapy development.  We are particularly engaged in translational trial platforms and are committed to building more inclusive science by examining how ancestry, and systemic stressors influence immune outcomes across populations.